Chia Ling Wang

Director/Board Member at UNITED BIOPHARMA INC

72 year

Consumer Services

Health Technology

Producer Manufacturing

Profile

Jia Ling Wang is currently a Director at Shanghai Baolong Automotive Corp., an Independent Director at United BioPharma, Inc., and a Professor at The Hong Kong University of Science & Technology.
Previously, Ms. Wang served as an Independent Non-Executive Director at Television Broadcasts Ltd.
from 2015 to 2021.
Ms. Wang received a graduate degree from Harvard University in 1977, an undergraduate degree from National Taiwan University in 1974, and a graduate degree from the University of Wisconsin-Milwaukee in 1976.

Chia Ling Wang active positions

Companies	Position	Start
UNITED BIOPHARMA INC	Director/Board Member	2014-09-29
SHANGHAI BAOLONG AUTOMOTIVE CORPORATION	Director/Board Member	2013-12-31
The Hong Kong University of Science & Technology	Corporate Officer/Principal	-

All active positions of Chia Ling Wang

Former positions of Chia Ling Wang

Companies	Position	End
TELEVISION BROADCASTS LIMITED	Director/Board Member	2021-05-25

See the detail of Chia Ling Wang's experience

Training of Chia Ling Wang

Harvard University	Graduate Degree
University of Wisconsin-Milwaukee	Graduate Degree
National Taiwan University	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Chia Ling Wang's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
TELEVISION BROADCASTS LIMITED	Consumer Services
SHANGHAI BAOLONG AUTOMOTIVE CORPORATION	Producer Manufacturing

Private companies	1
United BioPharma, Inc. United BioPharma, Inc. Pharmaceuticals: MajorHealth Technology United BioPharma, Inc. engages in the development, manufacture, and sale of monoclonal antibody drug. The company's business activities include the manufacture and sale of western drugs. Its products include trastumab, adalimumab, bevacizumab, rituximab, and omalizumab. The company was founded by Chang Yi Wang on September 30, 2013 and is headquartered in Hsinchu, Taiwan.	Health Technology